ArticleNature metabolism2024
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
Abstract read
In one paragraph
Article in Nature metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers.
0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed.
- Three-Dimensional Vector MR Elastography for Evaluating Tissue Mechanical Heterogeneity to Assess Liver Disease Progression.Radiology · 2025Trial
- Liver fibrosis: Pathogenesis and innovative nanoparticle-based therapeutic strategies.International journal of pharmaceutics: X · 2026Review
- Article
- Efficient sampling of liver tissue for histological analysis of rodent MASLD/MASH models.Histology and histopathology · 2026Article
- Ethanol reshapes FFC-driven steatohepatitis through time-dependent fibrosis and lipid-droplet remodeling.American journal of physiology. Gastrointestinal and liver physiology · 2026Article
- mTORC1-TFEB/TFE3 signaling is associated with bile acid diversification during hepatic metabolic adaptation.Science advances · 2026Article
- Dietary composition and metabolic stress differentially affect the ovarian microenvironment in mice.GeroScience · 2026Article
- Nutriomic Technologies for Characterizing, Diagnosing, Clustering and Managing Chronic Liver Diseases: Precision Nutrition Implications.International journal of molecular sciences · 2026Review
- An antisense oligonucleotide targeting STK25 as a long-acting therapeutic candidate for early MASLD.Molecular therapy. Nucleic acids · 2026Article
- The monoacylglycerol acyltransferase 2 inhibitor VB-85387 reduces MASLD.Journal of lipid research · 2026Article
- Precision pathophysiology in steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Sexual dimorphism in the association of circulating TAM receptors-ligands with MASLD-related fibrosis.JHEP reports : innovation in hepatology · 2026Observational
- Unveiling the role of age in MASLD development and biological process activation: Implications for translational research.Journal of physiology and biochemistry · 2026Article
- Plant-Derived Exosome-like Nanovesicles for Metabolic Dysfunction-Associated Steatotic Liver Disease.Veterinary sciences · 2026Review
- Intestinal lipase inhibition uncouples diet-induced obesity from MASH by remodeling the hepatic lipidome in mice.Journal of lipid research · 2026Article
- TGFβ activity stabilizes ACC1 to increase de novo lipogenesis in metabolic liver disease.Molecular metabolism · 2026Article
- The Latest Therapeutic Targets and New Drug Research of Metabolic Dysfunction-Associated Steatotic Liver Disease.Clinical pharmacology and therapeutics · 2026Review
- Integrating WGCNA and machine learning to identify and validate key biomarkers in MASLD.BMC gastroenterology · 2026Article
- A data-driven framework reconstructs the molecular continuum of human MASLD progression.Nature metabolism · 2026Article
- Mitochondrial Communication with Cellular Organelles in the Pathogenesis of Fatty Liver Disease in Domestic and Model Animals.Animals : an open access journal from MDPI · 2026Review
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
59 authors.
Michele Vacca *TVP Lab, WT/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK. michele.vacca@uniba.it.ORCID http://orcid.org/0000-0002-1973-224X
Ioannis Kamzolas *TVP Lab, WT/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-7408-5284
Lea Mørch Harder *Research and Early Development, Novo Nordisk A/S, Måløv, Copenhagen, Denmark.ORCID http://orcid.org/0009-0007-6126-3380
Fiona OakleyNewcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0001-8692-1836
Christian TrautweinDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID http://orcid.org/0000-0003-2762-8247
Maximilian HattingDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Trenton RossInternal Medicine research Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, USA.
Barbara BernardoInternal Medicine research Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, USA.ORCID http://orcid.org/0009-0000-6272-4272
Anouk OldenburgerCardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
Sara Toftegaard HjulerResearch and Early Development, Novo Nordisk A/S, Måløv, Copenhagen, Denmark.
Iwona KsiazekNovartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.ORCID http://orcid.org/0000-0003-3825-6848
Daniel LindénBioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gothenburg, Sweden.ORCID http://orcid.org/0000-0003-4158-8018
Detlef SchuppanInstitute of Translational Immunology and Research Center for Immunotherapy, Johannes Gutenberg University Medical Center, Mainz, Germany.ORCID http://orcid.org/0000-0002-4972-1293
Sergio Rodriguez-CuencaTVP Lab, WT/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Maria Manuela ToniniLuxembourg Institute of Health, Translational Medicine Operations Hub, Dudelange, Luxembourg.
Tamara R CastañedaR&D Diabetes & Portfolio Innovation and Excellence, Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt, Germany.
Aimo KanntR&D Diabetes, Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt, Germany.ORCID http://orcid.org/0000-0002-5197-2286
Cecília M P RodriguesResearch Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.ORCID http://orcid.org/0000-0002-4829-754X
Simon CockellBioinformatics Support Unit, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Olivier GovaereTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0002-4426-6930
Ann K DalyTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Michael AllisonLiver Unit, Cambridge University Hospitals NHS Foundation Trust & Cambridge NIHR Biomedical Research Centre, Cambridge, UK.ORCID http://orcid.org/0000-0003-3677-3294
Kristian Honnens de LichtenbergResearch and Early Development, Novo Nordisk A/S, Måløv, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-3905-9574
Yong Ook KimInstitute of Translational Immunology and Research Center for Immunotherapy, Johannes Gutenberg University Medical Center, Mainz, Germany.ORCID http://orcid.org/0000-0003-3557-2028
Anna LindblomBioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gothenburg, Sweden.ORCID http://orcid.org/0000-0003-4903-1759
Stephanie OldhamBioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gaithersburg, MD, USA.
Anne-Christine AndréassonBioscience Cardiovascular, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gothenburg, Sweden.
Franklin SchlermanInflammation and Immunology Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-9767-0670
Jonathon MarioneauxFleur De Lis Holdings 10201 Dakins Dr. Richmond, Richmond, VA, USA.
Arun SanyalDepartment of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Marta B AfonsoResearch Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.ORCID http://orcid.org/0000-0003-3011-4941
Ramy YounesTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Yuichiro AmanoResearch, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Scott L FriedmanDivision of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-1178-6195
Shuang WangDivision of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5037-4316
Dipankar BhattacharyaDivision of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Eric SimonGlobal Computational Biology and Digital Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.ORCID http://orcid.org/0000-0002-2585-3830
Valérie ParadisDepartment of Imaging and Pathology, Université Paris Diderot and Hôpital Beaujon, Paris, France.
Alastair BurtTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Ioanna Maria GrypariDepartment of Pathology, Aretaeion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0001-6042-6554
Susan DaviesDepartment of Cellular Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Ann DriessenDepartment of Pathology, Antwerp University Hospital, Edegem, Belgium.
Hiroaki YashiroResearch, Takeda Pharmaceuticals Company Limited, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5934-6469
Susanne PorsGubra, Hoersholm, Denmark.
Maja Worm AndersenGubra, Hoersholm, Denmark.ORCID http://orcid.org/0000-0002-4574-5810
Michael FeighGubra, Hoersholm, Denmark.ORCID http://orcid.org/0000-0001-5274-8799
Carla YunisPfizer, Inc.; Internal Medicine and Hospital, Pfizer Research and Development, Lake Mary, FL, USA.ORCID http://orcid.org/0009-0002-4280-3429
Pierre BedossaTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Michelle StewartMary Lyon Centre, MRC Harwell, Harwell Campus, Oxford, UK.
Heather L CaterMary Lyon Centre, MRC Harwell, Harwell Campus, Oxford, UK.
Sara WellsMary Lyon Centre, MRC Harwell, Harwell Campus, Oxford, UK.ORCID http://orcid.org/0000-0002-0572-0600
Jörn M SchattenbergDepartment of Internal Medicine II, Saarland University Medical Centre, Homburg, Germany.ORCID http://orcid.org/0000-0002-4224-4703
Quentin M AnsteeTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0002-9518-0088
LITMUS Investigators
Dina TiniakosTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK. Dina.Tiniakos@newcastle.ac.uk.ORCID http://orcid.org/0000-0003-4657-7780
James W PerfieldLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA. Perfield_james_w@lilly.com.ORCID http://orcid.org/0000-0003-0261-1780
Evangelia PetsalakiEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, UK. petsalaki@ebi.ac.uk.ORCID http://orcid.org/0000-0002-8294-2995
Peter DavidsenResearch and Early Development, Novo Nordisk A/S, Måløv, Copenhagen, Denmark. pkdavidsen@gmail.com.ORCID http://orcid.org/0009-0003-7703-9464
Antonio Vidal-PuigTVP Lab, WT/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK. ajv22@medschl.cam.ac.uk.ORCID http://orcid.org/0000-0003-4220-9577
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MHepatic stellate cells in NASH fibrosis and HCCR01DK128289 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCOTT L. FRIEDMAN · 2021 to 2026
$2.6MHepatic stellate cell plasticity and maladaptive fibrogenic memory in chronic liver diseaseR01DK136016 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Shuang Wang · 2023 to 2026
$2.3MAssociazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG27521Foundation for Liver Research IntramuralFundacin Espaola para la Ciencia y la Tecnologa (Spanish Foundation for Science and Technology) PTDC/MED-FAR/3492/2021Innovative Medicines Initiative (IMI) 777377la Caixa Foundation (Caixa Foundation) LCF/PR/HR21/52410028Medical Research Council MR/K001949/1Ministero dellapos;Istruzione, dellapos;Universit e della Ricerca (Ministry of Education, University and Research) CN00000013Ministero dellapos;Istruzione, dellapos;Universit e della Ricerca (Ministry of Education, University and Research) CN00000041Ministero dellapos;Istruzione, dellapos;Universit e della Ricerca (Ministry of Education, University and Research) P202222FCCMinistero dellapos;Istruzione, dellapos;Universit e della Ricerca (Ministry of Education, University and Research) PE00000003NCI NIH HHS P30 CA196521NIDDK NIH HHS R01 DK128289NIDDK NIH HHS R01 DK136016RCUK | Medical Research Council (MRC) 1948243RCUK | Medical Research Council (MRC) MR/K0019494/1RCUK | Medical Research Council (MRC) MR/R023026/1Universita degli Studi di Bari Aldo Moro (University of Bari Aldo Moro) S06-miRNASHU.S. Department of Health Human Services | NIH | NIH Clinical Center (Clinical Center) NCI 5P30CA196521-08U.S. Department of Health Human Services | NIH | NIH Clinical Center (Clinical Center) NIH R01 DK128289U.S. Department of Health Human Services | NIH | NIH Clinical Center (Clinical Center) NIH R01 DK136016
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD 'human proximity score' to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that Western diets align closely with human MASH; high cholesterol content, extended study duration and/or genetic manipulation of disease-promoting pathways are required to intensify liver damage and accelerate significant (F2+) fibrosis development. Choline-deficient models rapidly induce MASH-fibrosis while showing relatively poor translatability. Our ranking of commonly used MASLD models, based on their proximity to human MASLD, helps with the selection of appropriate in vivo models to accelerate preclinical research.
Indexed as
Disease Models, AnimalNon-alcoholic Fatty Liver DiseaseAnimalsDiet, WesternHumansLiverLiver CirrhosisMaleMetabolic DiseasesMiceRetrospective Studies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.